Zecen Biotech

About Zecen Biotech

Jiangsu ZECEN Biotechnology Co., Ltd., established in August 2011, is a developer and manufacturer of in-vitro diagnostic (IVD) devices and reagents, specializing in the chemiluminescence immunoassay (CLIA) field. The company's legal representative is Liu Zhengguo. Corporate headquarters are located in the China Medical City in Taizhou, Jiangsu, with research and development centers in Beijing, and production bases in Weifang, Shandong, and Taizhou.

ZECEN provides fully automatic chemiluminescence immunoassay analyzers and corresponding reagent kits. Its product portfolio is centered around chemiluminescence and point-of-care testing (POCT) solutions, supplemented by biochemical products. The company has independently developed a tubular chemiluminescence immunoassay system that combines magnetic particles as a solid phase with the chemiluminescence method, which enhances detection sensitivity and analysis speed. Their product line includes over 100 assays for diagnosing a variety of conditions related to thyroid, inflammation, diabetes, tumor markers, immune disorders, hormones, and cardiac markers. The business model involves the research, development, production, and sale of these IVD instruments and reagents to clients such as hospitals, disease control centers, and physical examination centers. ZECEN also offers OEM, ODM, and other customized services.

The company's history includes several key milestones. In 2013, it obtained registration for its CIA1200 analyzer and 23 reagent kits. It was recognized as a National High-Tech Enterprise in 2014 and entered its first overseas market in 2015. By 2016, ZECEN had acquired Weifang Zecheng to broaden its product line and received CE and ISO13485 certifications. The company has established collaborations with numerous hospitals in China and has expanded its international presence to regions including Southeast Asia, Latin America, and Europe.